Avrio Capital Inc. is a venture capital and private equity investment firm based in Alberta, Canada, with additional offices in Ontario and Quebec. Founded in 2006, the firm specializes in investing in commercialization to growth-stage companies, particularly in sectors such as food technology, advanced agriculture, industrial bioproducts, and nutraceutical ingredients. Avrio Capital focuses on innovative businesses that address global challenges related to health, wellness, and sustainability. The firm targets investments ranging from CAD $1 million to CAD $10 million, reserving significant capital for future financing rounds. It primarily seeks to invest in companies with annual sales between CAD $1 million and CAD $20 million, and it prefers to take an active role in its investments. Avrio Capital emphasizes its commitment to companies based in Canada and North America.
FarmLead Resources Ltd. operates a digital marketplace that allows buyers and sellers to list, negotiate, and finalize grain deals. The company offers GrainTests.com, an online service that allows grain farmers to test their grain. It serves farms in North America. Its marketplace is available online and as a mobile application. The company was founded in 2013 and is based in Ottawa, Canada. It has operations in Alberta, Saskatchewan, Manitoba, and Ontario.
Advitech is a life science and technology company with the mission to discover and commercialize patented, scientifically supported natural health products. Effective and safe, these products target immune system disorders, such as psoriasis and inflammatory bowel disease. Advitech produces Dermylex (R) for the treatment of mild to moderate psoriasis. Advitech has developed a research program to develop new applications in the field of wound healing. This development program stems from the two technological platforms XP-828L and IM.
Advitech is a life science and technology company with the mission to discover and commercialize patented, scientifically supported natural health products. Effective and safe, these products target immune system disorders, such as psoriasis and inflammatory bowel disease. Advitech produces Dermylex (R) for the treatment of mild to moderate psoriasis. Advitech has developed a research program to develop new applications in the field of wound healing. This development program stems from the two technological platforms XP-828L and IM.